Core Viewpoint - The company, 泰德医药 (03880.HK), has received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its conversion and listing, indicating that the filing process has been completed [1] Group 1 - The company received the filing notice on February 5, 2026, confirming the completion of the CSRC filing for conversion and listing [1] - If the company does not complete the share conversion within 12 months from the date of the filing notice, it must update the filing materials with the CSRC [1] - The details of the implementation plan for the conversion and listing have not yet been finalized as of the announcement date [1]

Core Viewpoint - The company, 泰德医药 (Tide Pharmaceutical), has received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its conversion and listing process, indicating that the filing has been completed [1] Group 1: Filing and Listing Process - The company received the filing notice on February 5, 2026, confirming the completion of the CSRC filing for conversion and listing [1] - If the company does not complete the share conversion within 12 months from the issuance of the filing notice, it must update the CSRC with new filing materials if it wishes to continue the process [1] - Details of the implementation plan for the conversion and listing have not yet been finalized as of the announcement date [1] Group 2: Compliance and Future Announcements - The company will make further announcements regarding the progress of the conversion and listing in accordance with listing rules and applicable laws and regulations [1]

Core Viewpoint - The company, 泰德医药 (03880), has received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its conversion and listing, indicating that the filing process has been completed [1] Group 1: Filing and Listing Process - The company received the filing notice on February 5, 2026, confirming the completion of the CSRC filing for conversion and listing [1] - If the company does not complete the share conversion within 12 months from the date of the filing notice, it must update the filing materials to the CSRC for further progress [1] - Details regarding the implementation plan for the conversion and listing have not yet been finalized as of the announcement date [1] Group 2: Compliance and Future Announcements - The company will make further announcements regarding the progress of the conversion and listing in accordance with listing rules and applicable laws and regulations [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Medtide Inc. 泰 德 醫 藥（ 浙 江 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3880） 內幕消息 中國證監會就本公司H股全流通申請 發出備案通知書 本公告乃由泰德醫藥（浙江）股份有限公司（「本公司」）根據香港聯合交易所有限公 司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及內幕消息條文（定義 見上市規則，即香港法例第571章證券及期貨條例第XIVA部）作出。 泰德醫藥（浙江）股份有限公司 茲提述本公司日期為2025年7月27日的公告，內容有關中國證監會受理本公司H 股全流通計劃的申請（「該公告」）。除本公告另有界定外，本公告所用詞彙與該公 告所界定者具有相同涵義。 董事會欣然宣佈，本公司於2026年2月5日收到中國證監會就轉換並上市向本公 司發出的備案通知書（「備案通知書」）。根據備案通知書，有關轉換並上市的中國 證監會備 ...

Group 1 - The core viewpoint of the news is that TaiDe Pharmaceutical (03880.HK) has experienced a significant decline in its stock price, reaching a record low since its listing, indicating a state of underperformance in the market [1] - The stock closed at HKD 23.42, reflecting a drop of 5.565%, with an intraday low of HKD 21.50, marking the lowest price since its IPO [1] - TaiDe Pharmaceutical was listed on the Hong Kong Stock Exchange on June 30, 2025, with a total of 16,800,000 H-shares issued, split evenly between public and international offerings [1] Group 2 - The final offering price for TaiDe Pharmaceutical was HKD 30.6, resulting in total proceeds of HKD 514.08 million, with net proceeds amounting to HKD 428.77 million after deducting estimated listing expenses of HKD 85.31 million [1] - The cornerstone investors for TaiDe Pharmaceutical include Shiyao and Welight Capital, indicating strategic backing from established entities in the industry [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） FF301 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | ...

Core Viewpoint - 泰德医药's stock is currently in a downtrend, having reached its lowest price since listing, indicating potential concerns regarding its market performance and investor confidence [1]. Group 1: Stock Performance - 泰德医药's stock closed at 27.28 HKD, with a decline of 2.502% on the day [1]. - The stock hit a low of 25.78 HKD during trading, marking the lowest price since its IPO [1]. - Since its listing, 泰德医药 has experienced a cumulative decline of 10.85% [1]. Group 2: IPO Details - 泰德医药 was listed on the Hong Kong Stock Exchange on June 30, 2025, with a final offer price of 30.6 HKD per share [1]. - A total of 16,800,000 H-shares were issued, with 8,400,000 shares allocated for public offering in Hong Kong and 8,400,000 shares for international offering [1]. - The total proceeds from the IPO amounted to 514.08 million HKD, with net proceeds of 428.77 million HKD after deducting estimated listing expenses of 85.31 million HKD [1]. Group 3: Underwriters and Investors - The joint sponsors and underwriters for 泰德医药 include Morgan Stanley, CITIC Securities, and others [1]. - Key cornerstone investors for 泰德医药 are 石药 and Welight Capital [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 備註： 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 | RMB | | 73,598,888 | | ...

Core Viewpoint - The stock price of TIDE Pharmaceuticals (03880) has experienced a significant decline since its IPO, reaching a new low, but has recently shown signs of recovery ahead of the cornerstone lock-up expiration on December 30 [1][4]. Group 1: Stock Performance - TIDE Pharmaceuticals' stock price peaked at 41.72 HKD on August 21, shortly after its IPO on June 30, but subsequently fell below the issue price of 30.60 HKD due to market fluctuations [1][4]. - The stock exhibited a "V-shaped" pattern, with an initial rise followed by a decline, characterized by a significant drop in trading volume and price [2][3]. - A recent "eight consecutive days of gains" has brought the stock price back to 30.26 HKD, just shy of the issue price, indicating a potential recovery [4]. Group 2: Market Context and Competition - The global peptide drug market is projected to grow from 60.7 billion USD in 2018 to 89.5 billion USD in 2023, with a compound annual growth rate (CAGR) of 8.1%, and expected to reach 261.2 billion USD by 2032 [5]. - The Chinese peptide drug market is also expanding, with a forecasted growth from 48.2 billion RMB in 2018 to 59.7 billion RMB in 2023, and a CAGR of 17.3% anticipated until 2032 [6]. - The GLP-1 market is becoming increasingly competitive, with nearly 200 drugs in development globally, leading to concerns about profit margins and market saturation [7]. Group 3: Company Operations and Financials - TIDE Pharmaceuticals operates globally, serving over 1,000 clients across more than 50 countries, with a high client retention rate of over 90% [8]. - The company reported revenues of approximately 351 million RMB in 2022, with projections of 337 million RMB in 2023 and 442 million RMB in 2024, alongside significant growth in overseas revenue driven by demand for GLP-1 related drug development [8]. - The company's financial performance for the first half of 2025 showed a revenue increase of 28.52% year-on-year, with a net profit increase of 101.71% [8].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 泰德醫藥（浙江）股份有限公司（「本公司」） 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03880 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 73,598,888 | RMB | | 1 RMB | | 73,598,888 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 73,598,888 | RMB | | 1 RMB | | 73,598,888 | | 2. 股份分類 | 普通股 | 股份類別 ...